Open Access. Powered by Scholars. Published by Universities.®

Nanoscience and Nanotechnology Commons

Open Access. Powered by Scholars. Published by Universities.®

Articles 1 - 2 of 2

Full-Text Articles in Nanoscience and Nanotechnology

Exploration Of Antimicrobial And Cell Proliferation Properties Of Nanofibers Incorporating Nopal (O. Cochenillifera) Extract, Cristobal Rodriguez May 2021

Exploration Of Antimicrobial And Cell Proliferation Properties Of Nanofibers Incorporating Nopal (O. Cochenillifera) Extract, Cristobal Rodriguez

Theses and Dissertations

This study focused on the fabrication of Forcespinning® nanofibers composed of Opuntia cochenillifera, ‘nopal’, mucilage (N) extract, chitosan (CH), and pullulan (PL) (N/CH/PL) were developed with an optimum fiber average diameter of 406±127 nm, and studied for their ability to sustain adhesion and proliferation of mouse embryonic fibroblast (NIH 3T3) cells. After a 6-day incubation period, N/CH/PL nanofibers displayed robust cell proliferation, while also exhibiting inhibitory properties through an N extract dip-coating process against gram-negative bacteria Escherichia coli in a 24 h bacterial growth study. A demonstration of integrated natural bioactive compounds with combined biodegradable polymers, provide an enhanced …


Fibrinogen-Conjugated Gold-Coated Magnetite Nanoparticles For Antiplatelet Therapy, Evan Schuerer Krystofiak Aug 2013

Fibrinogen-Conjugated Gold-Coated Magnetite Nanoparticles For Antiplatelet Therapy, Evan Schuerer Krystofiak

Theses and Dissertations

Ischemic stroke is the world's second leading cause of death and accounts for 2-4% of total worldwide healthcare costs. Ischemic stroke is caused by the occlusion of arteries responsible for supplying blood to the brain, which can result in disability or death. Arterial blood clots consist of aggregates of activated platelets wrapped in a mesh of fibrin. Tissue plasminogen activator, the only current FDA-approved treatment for ischemic stroke, functions by lysing fibrin in a blood clot. Unfortunately, tissue plasminogen activator significantly increases bleeding risks, which restricts its use. Alternatively, targeting and disrupting platelets within a clot could improve stroke outcome. …